As expected, in association with its BRCAwt status and its reported in vitro resistance to olaparib [65,66], Hs578T revealed no alterations in proliferation rate, no increase in activated caspase 3 or decrease in tumor size. The gene discussed is CASP3; the disease is neoplasm.